Stay updated on Atezolizumab vs Durvalumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page.

Latest updates to the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe site revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page displays a 403 Forbidden error with a minimal header instead of the study record content. This indicates an access issue rather than a substantive update to the page's materials.SummaryDifference18%

- Check45 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6 on the page footer, indicating a software release; no study details or results appear to be altered.SummaryDifference0.0%

- Check52 days agoChange DetectedA funding attribution line indicating a 2019 U.S. NIH grant/contract was added. This addition provides funding source context but does not alter study details or eligibility.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page revision tag was updated to v3.6.5, replacing the previous v3.6.4, reflecting a minor update to the page version.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page now shows Revision: v3.6.4 in the site metadata, replacing the previous v3.6.3. This change reflects a software release and does not alter study information or data.SummaryDifference0.0%

Stay in the know with updates to Atezolizumab vs Durvalumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page.